Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
| Image |  |
|---|---|
| Description | scientific article published on 10 August 2006 |
| Author/s |
author: Nick Holford Michael C. Heinrich Michael A Caligiuri Brian Druker |
| Publication date | August 10, 2006 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |